Women and clinicians are regularly reminded about the threat of breast cancer by the media, advertisements, and the experiences of friends or family members who are fighting the disease. And there is good reason for breast cancer to be prominent in our consciousness: The breast is the leading site of cancer in US women (32% [...]
Holmberg and Anderson recently published a research letter in the journal Lancet regarding early cessation of the HABITS study,1 a Scandinavian trial designed to evaluate the risk of breast cancer recurrence in women with previously treated breast cancers who were given hormone therapy (HT) for relief of menopausal symptoms. The primary objective of the study [...]
Women with a history of breast cancer have been advised to avoid estrogen replacement therapy (ERT). A reassessment of this approach has been initiated by several authors and clinical reports to date have not supported this tenet. The only prospective randomized trial reported to date is that of Vassilopoulou-Sellin et al. The authors conducted a [...]
Baseline incidence of invasive breast cancers in non-HRT users is 32/1000 between ages 50 and 65 years. Baseline incidence of endometrial cancers in non-HRT users is 5/1000 between ages 50 and 64 years.
The excess risk of breast cancer with long-term use (10 years) of 19/1000 EPT and 5/1000 for ET alone can be compared with [...]
Recent findings from a large observational study conducted in Great Britain show that current use – but not past use- of postmenopausal therapy is associated with an increased risk of breast cancer as well as an increased incidence of breast cancer fatalities.
This large cohort study1 confirms the findings from the Women’s Health Initiative (WHI) (2,3) [...]
In an article in Brainwork J. Kinoshita speculated in the kind of way that inspires drug houses to finance the running of large-scale clinical trials, in this case of the effects of estrogen given in the post menopausal age on the incidence of Alzheimer’s disease. Elderly women are more prone than men to Alzheimer’s, but [...]
